Growth Metrics

Cellectis (CLLS) Cost of Revenue (2015 - 2023)

Cellectis (CLLS) posted Cost of Revenue of -$344000.0 for Q4 2023, down 193.73% on a QoQ basis from $367000.0 in Q3 2023, and down 149.86% year-over-year from $690000.0 in Q4 2022.

Cellectis (CLLS) has 9 years of Cost of Revenue data on file, last reported at -$344000.0 in Q4 2023.

  • In Q4 2023, Cost of Revenue fell 149.86% year-over-year to -$344000.0; the TTM figure through Dec 2023 stood at $412000.0 (down 76.74% YoY), while the FY2023 annual figure was $737000.0, down 58.41% from the prior year.
  • Cost of Revenue slipped to -$344000.0 in Q4 2023, from $367000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $18.6 million in Q4 2020 and bottomed at -$344000.0 in Q4 2023.
  • A 5-year average of $4.0 million and a median of $752500.0 in 2019 frame the typical range for Cost of Revenue.
  • Annual changes were most pronounced in 2019 — Cost of Revenue soared 685.0% — and 2023, when it plunged 149.86%.
  • Year by year, Cost of Revenue stood at $5.7 million in 2019, then jumped by 229.87% to $18.6 million in 2020, then slumped by 98.7% to $243000.0 in 2021, then jumped by 183.95% to $690000.0 in 2022, then plunged by 149.86% to -$344000.0 in 2023.
  • The last three Cost of Revenue figures came in at -$344000.0 (Q4 2023), $367000.0 (Q3 2023), and $55000.0 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 64.20 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 392.80 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 296.00 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 207.52 Mn
10 Cellectis 20.83 Bn 20.62 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 167,000.00
Dec 31, 2023 167,000.00
Sep 30, 2023 367,000.00
Sep 30, 2023 367,000.00
Jun 30, 2023 55,000.00
Jun 30, 2023 55,000.00
Mar 31, 2023 334,000.00
Mar 31, 2023 334,000.00
Dec 31, 2022 690,000.00
Dec 31, 2022 690,000.00
Sep 30, 2022 367,000.00
Sep 30, 2022 367,000.00
Jun 30, 2022 329,000.00
Jun 30, 2022 329,000.00
Mar 31, 2022 385,000.00
Mar 31, 2022 385,000.00
Dec 31, 2021 243,000.00
Dec 31, 2021 243,000.00
Sep 30, 2021 9.21 Mn
Sep 30, 2021 9.21 Mn
Jun 30, 2021 11.75 Mn
Jun 30, 2021 11.75 Mn
Mar 31, 2021 8.15 Mn
Mar 31, 2021 8.15 Mn
Dec 31, 2020 18.64 Mn
Dec 31, 2020 18.64 Mn
Sep 30, 2020 7.82 Mn
Sep 30, 2020 7.82 Mn
Jun 30, 2020 5.83 Mn
Jun 30, 2020 5.83 Mn
Mar 31, 2020 4.60 Mn
Mar 31, 2020 4.60 Mn
Dec 31, 2019 5.65 Mn
Dec 31, 2019 5.65 Mn
Sep 30, 2019 4.26 Mn
Sep 30, 2019 4.26 Mn
Jun 30, 2019 815,000.00
Jun 30, 2019 815,000.00
Mar 31, 2019 586,000.00
Mar 31, 2019 586,000.00
Dec 31, 2018 720,000.00
Dec 31, 2018 720,000.00
Sep 30, 2018 868,000.00
Sep 30, 2018 868,000.00
Jun 30, 2018 559,000.00
Jun 30, 2018 559,000.00
Mar 31, 2018 579,000.00
Mar 31, 2018 579,000.00
Dec 31, 2017 883,000.00
Dec 31, 2017 883,000.00
Sep 30, 2017 569,000.00
Sep 30, 2017 569,000.00
Jun 30, 2017 563,000.00
Jun 30, 2017 563,000.00
Mar 31, 2017 611,000.00
Mar 31, 2017 611,000.00
Dec 31, 2016 616,000.00
Dec 31, 2016 616,000.00
Sep 30, 2016 348,000.00
Sep 30, 2016 348,000.00
Jun 30, 2016 328,793.63
Jun 30, 2016 328,793.63
Mar 31, 2016 477,604.28
Mar 31, 2016 477,604.28
Dec 31, 2015 1.45 Mn
Dec 31, 2015 1.45 Mn
Sep 30, 2015 371,503.16
Sep 30, 2015 371,503.16
Jun 30, 2015 433,215.38
Jun 30, 2015 433,215.38
Mar 31, 2015 482,438.47
Mar 31, 2015 482,438.47